Concepts (183)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Transcranial Magnetic Stimulation | 27 | 2023 | 413 | 4.430 |
Why?
|
| Prefrontal Cortex | 22 | 2023 | 640 | 3.710 |
Why?
|
| Tobacco Use Disorder | 12 | 2023 | 432 | 2.700 |
Why?
|
| Smoking Cessation | 8 | 2023 | 1034 | 1.810 |
Why?
|
| Triazines | 5 | 2011 | 48 | 1.360 |
Why?
|
| Craving | 5 | 2017 | 200 | 1.320 |
Why?
|
| Magnetic Resonance Imaging | 29 | 2023 | 2223 | 1.150 |
Why?
|
| Cues | 16 | 2017 | 654 | 1.130 |
Why?
|
| Valproic Acid | 3 | 2011 | 93 | 1.030 |
Why?
|
| Smoking | 6 | 2020 | 1452 | 0.950 |
Why?
|
| Bipolar Disorder | 5 | 2014 | 307 | 0.900 |
Why?
|
| Neurofeedback | 5 | 2016 | 34 | 0.850 |
Why?
|
| Cerebral Cortex | 4 | 2011 | 415 | 0.830 |
Why?
|
| Anticonvulsants | 4 | 2011 | 223 | 0.780 |
Why?
|
| Gyrus Cinguli | 4 | 2015 | 113 | 0.710 |
Why?
|
| Functional Laterality | 6 | 2013 | 240 | 0.670 |
Why?
|
| Neural Inhibition | 3 | 2017 | 80 | 0.660 |
Why?
|
| Adult | 42 | 2023 | 21403 | 0.610 |
Why?
|
| Double-Blind Method | 10 | 2023 | 1738 | 0.610 |
Why?
|
| Depressive Disorder, Major | 6 | 2015 | 439 | 0.600 |
Why?
|
| Substance Withdrawal Syndrome | 5 | 2013 | 435 | 0.580 |
Why?
|
| Brain | 15 | 2018 | 2176 | 0.580 |
Why?
|
| Nerve Net | 2 | 2017 | 181 | 0.570 |
Why?
|
| Smokers | 1 | 2017 | 200 | 0.510 |
Why?
|
| Brain Mapping | 14 | 2018 | 532 | 0.510 |
Why?
|
| Limbic System | 2 | 2013 | 106 | 0.440 |
Why?
|
| Male | 40 | 2020 | 37321 | 0.420 |
Why?
|
| Amphetamine-Related Disorders | 1 | 2013 | 92 | 0.420 |
Why?
|
| Behavior, Addictive | 2 | 2013 | 317 | 0.420 |
Why?
|
| Schizophrenia | 3 | 2018 | 206 | 0.410 |
Why?
|
| Methamphetamine | 1 | 2013 | 132 | 0.390 |
Why?
|
| Humans | 49 | 2023 | 68618 | 0.380 |
Why?
|
| Central Nervous System Stimulants | 1 | 2013 | 221 | 0.380 |
Why?
|
| Female | 35 | 2020 | 38074 | 0.370 |
Why?
|
| Middle Aged | 26 | 2020 | 21147 | 0.370 |
Why?
|
| Motor Cortex | 3 | 2012 | 158 | 0.360 |
Why?
|
| Alcoholism | 7 | 2014 | 1109 | 0.360 |
Why?
|
| Central Nervous System Agents | 1 | 2009 | 37 | 0.320 |
Why?
|
| Reward | 3 | 2023 | 201 | 0.320 |
Why?
|
| Young Adult | 12 | 2017 | 5717 | 0.290 |
Why?
|
| Antidepressive Agents | 4 | 2023 | 216 | 0.270 |
Why?
|
| Single-Blind Method | 3 | 2017 | 249 | 0.260 |
Why?
|
| Functional Neuroimaging | 4 | 2015 | 82 | 0.260 |
Why?
|
| Dominance, Cerebral | 2 | 2011 | 65 | 0.250 |
Why?
|
| Adolescent | 11 | 2013 | 8912 | 0.250 |
Why?
|
| Time Factors | 6 | 2020 | 4655 | 0.240 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2005 | 137 | 0.240 |
Why?
|
| Photic Stimulation | 4 | 2013 | 229 | 0.240 |
Why?
|
| Calcium Channel Blockers | 1 | 2004 | 138 | 0.230 |
Why?
|
| Magnetics | 1 | 2004 | 52 | 0.230 |
Why?
|
| Depressive Disorder, Treatment-Resistant | 1 | 2023 | 29 | 0.220 |
Why?
|
| Alcohol Drinking | 5 | 2014 | 805 | 0.200 |
Why?
|
| Rest | 3 | 2018 | 78 | 0.200 |
Why?
|
| Treatment Outcome | 13 | 2023 | 7029 | 0.190 |
Why?
|
| Evoked Potentials, Motor | 4 | 2015 | 63 | 0.190 |
Why?
|
| Electroconvulsive Therapy | 3 | 2015 | 402 | 0.190 |
Why?
|
| Linear Models | 3 | 2012 | 521 | 0.180 |
Why?
|
| Oxygen | 4 | 2012 | 386 | 0.180 |
Why?
|
| Analysis of Variance | 4 | 2012 | 1040 | 0.180 |
Why?
|
| Pain | 4 | 2013 | 472 | 0.170 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 3259 | 0.170 |
Why?
|
| Naltrexone | 2 | 2012 | 195 | 0.160 |
Why?
|
| Pilot Projects | 6 | 2014 | 1342 | 0.160 |
Why?
|
| Image Processing, Computer-Assisted | 5 | 2013 | 689 | 0.150 |
Why?
|
| Pain Management | 2 | 2013 | 186 | 0.140 |
Why?
|
| Cigarette Smoking | 1 | 2018 | 104 | 0.140 |
Why?
|
| Motivation | 3 | 2014 | 561 | 0.140 |
Why?
|
| Basal Ganglia | 2 | 2008 | 45 | 0.140 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 3 | 2013 | 257 | 0.140 |
Why?
|
| Sensorimotor Cortex | 1 | 2015 | 18 | 0.130 |
Why?
|
| Electric Stimulation | 2 | 2008 | 218 | 0.130 |
Why?
|
| Corpus Striatum | 3 | 2013 | 279 | 0.130 |
Why?
|
| Cerebrovascular Circulation | 3 | 2008 | 296 | 0.120 |
Why?
|
| Antipsychotic Agents | 2 | 2010 | 247 | 0.120 |
Why?
|
| Electromagnetic Fields | 3 | 2003 | 66 | 0.120 |
Why?
|
| Depressive Disorder | 2 | 2012 | 621 | 0.120 |
Why?
|
| Smoking Prevention | 2 | 2013 | 259 | 0.110 |
Why?
|
| Nicotine | 1 | 2017 | 350 | 0.110 |
Why?
|
| Quinoxalines | 1 | 2014 | 78 | 0.110 |
Why?
|
| Benzazepines | 1 | 2014 | 104 | 0.110 |
Why?
|
| Cross-Over Studies | 4 | 2013 | 260 | 0.110 |
Why?
|
| Nicotinic Agonists | 1 | 2014 | 111 | 0.110 |
Why?
|
| Surveys and Questionnaires | 2 | 2020 | 2800 | 0.110 |
Why?
|
| Flumazenil | 1 | 2013 | 23 | 0.110 |
Why?
|
| Naloxone | 1 | 2013 | 56 | 0.110 |
Why?
|
| Movement Disorders | 2 | 2003 | 58 | 0.110 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2013 | 60 | 0.100 |
Why?
|
| Volition | 1 | 2012 | 16 | 0.100 |
Why?
|
| Movement | 1 | 2013 | 179 | 0.100 |
Why?
|
| Analgesia | 1 | 2013 | 58 | 0.100 |
Why?
|
| Receptors, Opioid, mu | 1 | 2012 | 70 | 0.100 |
Why?
|
| Amines | 1 | 2013 | 98 | 0.100 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2012 | 82 | 0.100 |
Why?
|
| Secondary Prevention | 3 | 2013 | 291 | 0.100 |
Why?
|
| Genetic Variation | 1 | 2012 | 220 | 0.100 |
Why?
|
| Combined Modality Therapy | 2 | 2004 | 951 | 0.100 |
Why?
|
| Sensation | 2 | 2009 | 49 | 0.100 |
Why?
|
| Seizures | 1 | 2013 | 279 | 0.100 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2013 | 208 | 0.090 |
Why?
|
| Electromyography | 2 | 2009 | 184 | 0.090 |
Why?
|
| Models, Neurological | 1 | 2011 | 136 | 0.090 |
Why?
|
| Cocaine-Related Disorders | 1 | 2015 | 504 | 0.090 |
Why?
|
| Placebos | 2 | 2008 | 195 | 0.090 |
Why?
|
| Quinolones | 1 | 2010 | 60 | 0.090 |
Why?
|
| Neural Pathways | 1 | 2011 | 324 | 0.080 |
Why?
|
| Piperazines | 1 | 2010 | 206 | 0.080 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2011 | 237 | 0.080 |
Why?
|
| Ondansetron | 1 | 2008 | 13 | 0.080 |
Why?
|
| Serotonin Antagonists | 1 | 2008 | 31 | 0.080 |
Why?
|
| Perception | 1 | 2009 | 189 | 0.080 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 2077 | 0.080 |
Why?
|
| Narcotics | 1 | 2008 | 65 | 0.080 |
Why?
|
| Mental Disorders | 2 | 2003 | 659 | 0.070 |
Why?
|
| Aged | 6 | 2012 | 14862 | 0.070 |
Why?
|
| Motor Activity | 1 | 2009 | 621 | 0.060 |
Why?
|
| Verbal Learning | 1 | 2005 | 29 | 0.060 |
Why?
|
| Brief Psychiatric Rating Scale | 1 | 2005 | 8 | 0.060 |
Why?
|
| Cross-Sectional Studies | 1 | 2011 | 2279 | 0.060 |
Why?
|
| Depression | 1 | 2012 | 943 | 0.060 |
Why?
|
| Memory, Short-Term | 1 | 2005 | 79 | 0.060 |
Why?
|
| Pain Measurement | 3 | 2013 | 328 | 0.060 |
Why?
|
| Skin | 1 | 2008 | 451 | 0.060 |
Why?
|
| Tourette Syndrome | 1 | 2004 | 8 | 0.060 |
Why?
|
| Alpha Rhythm | 1 | 2023 | 3 | 0.060 |
Why?
|
| Long-Term Care | 1 | 2004 | 53 | 0.060 |
Why?
|
| Indans | 1 | 2003 | 20 | 0.060 |
Why?
|
| Diffusion | 1 | 2003 | 90 | 0.050 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2003 | 58 | 0.050 |
Why?
|
| Piperidines | 1 | 2003 | 123 | 0.050 |
Why?
|
| Social Behavior | 1 | 2004 | 164 | 0.050 |
Why?
|
| Blood-Brain Barrier | 1 | 2003 | 99 | 0.050 |
Why?
|
| Electric Stimulation Therapy | 1 | 2004 | 147 | 0.050 |
Why?
|
| Acute Disease | 1 | 2004 | 658 | 0.050 |
Why?
|
| Affect | 1 | 2004 | 218 | 0.050 |
Why?
|
| Physical Therapy Modalities | 1 | 2003 | 133 | 0.050 |
Why?
|
| Water | 1 | 2003 | 230 | 0.050 |
Why?
|
| Cognition | 1 | 2005 | 513 | 0.050 |
Why?
|
| Narcotic Antagonists | 2 | 2013 | 184 | 0.050 |
Why?
|
| Cognition Disorders | 1 | 2003 | 342 | 0.040 |
Why?
|
| Severity of Illness Index | 3 | 2013 | 1851 | 0.040 |
Why?
|
| Algorithms | 1 | 2004 | 1196 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2013 | 649 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2015 | 1553 | 0.040 |
Why?
|
| Aftercare | 1 | 2016 | 114 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2016 | 111 | 0.030 |
Why?
|
| Skull | 2 | 2004 | 63 | 0.030 |
Why?
|
| Varenicline | 1 | 2014 | 98 | 0.030 |
Why?
|
| GABA Modulators | 1 | 2013 | 26 | 0.030 |
Why?
|
| Thalamus | 1 | 2013 | 82 | 0.030 |
Why?
|
| Tandem Repeat Sequences | 1 | 2012 | 13 | 0.030 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2013 | 128 | 0.030 |
Why?
|
| Individuality | 1 | 2012 | 44 | 0.030 |
Why?
|
| Imagination | 1 | 2012 | 38 | 0.030 |
Why?
|
| Body Temperature | 1 | 2012 | 116 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2012 | 219 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2012 | 301 | 0.020 |
Why?
|
| Arousal | 1 | 2011 | 168 | 0.020 |
Why?
|
| Anisotropy | 1 | 2011 | 105 | 0.020 |
Why?
|
| Aripiprazole | 1 | 2010 | 43 | 0.020 |
Why?
|
| Hippocampus | 1 | 2013 | 471 | 0.020 |
Why?
|
| Protein Binding | 1 | 2012 | 1027 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2012 | 627 | 0.020 |
Why?
|
| Electrodes | 1 | 2009 | 147 | 0.020 |
Why?
|
| Electric Impedance | 1 | 2009 | 131 | 0.020 |
Why?
|
| Patient Selection | 1 | 2012 | 592 | 0.020 |
Why?
|
| Dopamine | 1 | 2010 | 474 | 0.020 |
Why?
|
| South Carolina | 1 | 2013 | 2752 | 0.020 |
Why?
|
| Differential Threshold | 1 | 2004 | 27 | 0.020 |
Why?
|
| Likelihood Functions | 1 | 2004 | 106 | 0.010 |
Why?
|
| Reference Values | 1 | 2005 | 579 | 0.010 |
Why?
|
| Alcoholic Beverages | 1 | 2004 | 18 | 0.010 |
Why?
|
| Animals | 3 | 2009 | 20881 | 0.010 |
Why?
|
| Atrophy | 1 | 2004 | 112 | 0.010 |
Why?
|
| Beverages | 1 | 2004 | 50 | 0.010 |
Why?
|
| Demography | 1 | 2004 | 279 | 0.010 |
Why?
|
| Affective Symptoms | 1 | 2003 | 50 | 0.010 |
Why?
|
| Outpatients | 1 | 2003 | 127 | 0.010 |
Why?
|
| Motor Skills | 1 | 2003 | 88 | 0.010 |
Why?
|
| Software | 1 | 2004 | 418 | 0.010 |
Why?
|
| Memory | 1 | 2003 | 214 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2011 | 4848 | 0.010 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2003 | 782 | 0.010 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2002 | 931 | 0.010 |
Why?
|